儿童多系统炎症综合征中的巨噬细胞活化综合征
本研究在拉丁美洲16国84个中心的1238例MIS-C患儿中回顾性分析MAS的发生率、自然史、诊断指标、治疗与结局。212例(17.1%)符合MAS标准,MAS组胃肠道和神经系统表现更常见,死亡率12%且高于无MAS组。铁蛋白或红细胞沉降率比值>18.7诊断MAS的灵敏度88.2%、特异度75%。
要点
- MIS-C患儿中17.1%符合MAS标准,MAS组死亡率12%。
- MAS组胃肠道和神经系统表现更常见,死亡与MAS、惊厥、关节炎和休克相关。
- 铁蛋白或红细胞沉降率比值>18.7诊断MAS的灵敏度88.2%、特异度75%。
核心结论
- 在拉丁美洲最大的MIS-C队列中,MIS-C患儿的MAS与发病率和死亡率增加相关。
- 早期识别和适当管理对于改善患者结局和降低死亡率至关重要。
研究设计与样本
- 回顾性研究,纳入拉丁美洲16个国家84个中心的1238例MIS-C患者。
- 比较合并MAS与未合并MAS患者的临床和实验室特征。
主要发现
- 1238例MIS-C患者中212例(17.1%)符合MAS标准。
- MIS-C合并MAS的患者胃肠道和神经系统表现更频繁。
- MIS-C合并MAS的患者死亡率为12%,高于未合并MAS者。
- 死亡与MAS、惊厥、关节炎和休克相关。
关键数值与推荐
- 铁蛋白或红细胞沉降率比值>18.7诊断MIS-C中MAS的灵敏度为88.2%,特异度为75%。
临床怎么用
- 对MIS-C患儿应警惕MAS,尤其出现胃肠道或神经系统表现时。
- 铁蛋白或红细胞沉降率比值>18.7可辅助诊断MIS-C中的MAS。
- 早期识别MAS并给予免疫调节治疗可能改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multisystem inflammatory syndrome (MIS-C) represents a diagnostic challenge because of its overlap with Kawasaki disease, Kawasaki disease shock syndrome, and toxic shock syndrome. Macrophage activation syndrome (MAS) is a frequently fatal complication of various pediatric inflammatory disorders and has been reported in MIS-C. Early diagnosis and prompt initiation by immune modulating therapies are essential for effectively managing MAS. METHODS: We conducted a retrospective study to determine the frequency, natural history, diagnostic metrics, treatment, and outcome of MAS in MIS-C within a large cohort of patients across 84 Latin American centers in 16 countries. We compared the clinical and laboratory characteristics between patients with and without MAS. RESULTS: Among 1238 patients with MIS-C, 212 (17.1%) fulfilled MAS criteria. Gastrointestinal and neurologic manifestations were more frequent in cases where MIS-C was complicated by MAS. Patients presenting with MIS-C complicated by MAS had a mortality rate of 12%, which was higher than those without it. Mortality was associated with MAS, seizures, arthritis, and shock. A ferritin or erythrocyte sedimentation rate ratio of >18.7 exhibited a sensitivity of 88.2% and a specificity of 75% in diagnosing MAS in MIS-C. CONCLUSIONS: MAS in MIS-C patients is associated with increased morbidity and mortality rates in the largest MIS-C Latin American cohort. Early recognition and appropriate management are crucial in improving patient outcomes and reducing mortality rates.
引用
- Gámez-González LB, Murata C, García-Silva J, et al. Macrophage Activation Syndrome in MIS-C. Pediatrics. 2024. PMID: 39539128. doi:10.1542/peds.2024-066780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。